<p>Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - 获取免费报告) 的股价在周四的午盘交易中上涨了 4.4%。该股最高交易价格为 14.01 美元，最后交易价格为 14.04 美元。交易期间大约有 449,627 股成交，较日均成交量 2,224,287 股下降了 80%。该股此前收盘价为 13.45 美元。</p>
<p>获取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>几位股票研究分析师对 SNDX 股票发布了报告。花旗集团将 Syndax Pharmaceuticals 的目标股价从 46.00 美元上调至 51.00 美元，并在 8 月 5 日的研究报告中给予该公司 &#34;买入&#34; 评级。BTIG Research 将 Syndax Pharmaceuticals 的目标股价从 43.00 美元上调至 56.00 美元，并在 8 月 5 日的研究报告中给予该公司 &#34;买入&#34; 评级。加拿大丰业银行将 Syndax Pharmaceuticals 的目标股价从 16.00 美元上调至 17.00 美元，并在 5 月 6 日的研究报告中给予该公司 &#34;行业表现&#34; 评级。瑞银集团将 Syndax Pharmaceuticals 的目标股价从 37.00 美元下调至 35.00 美元，并在 7 月 15 日的研究报告中给予该公司 &#34;买入&#34; 评级。最后，古根海姆在 5 月 6 日的研究报告中重申了 &#34;买入&#34; 评级，并将 Syndax Pharmaceuticals 的目标股价设定为 32.00 美元。一位分析师给予该股 &#34;卖出&#34; 评级，一位给予 &#34;持有&#34; 评级，十位给予 &#34;买入&#34; 评级，一位给予 &#34;强力买入&#34; 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 &#34;适度买入&#34;，共识目标价为 36.91 美元。</p>
<p><strong>查看我们最新的 SNDX 股票分析</strong></p>
<h2>Syndax Pharmaceuticals 股价上涨 6.6%</h2>
<p>该股市值为 12.4 亿美元，市盈率为 -3.69，贝塔值为 0.74。该公司的流动比率为 4.71，速动比率为 4.55，债务与股本比率为 2.06。该股的 50 日移动平均价格为 10.20 美元，200 日移动平均价格为 11.88 美元。</p>
<p>Syndax Pharmaceuticals (NASDAQ:SNDX - 获取免费报告) 最近在 8 月 4 日发布了季度财报。该公司报告季度每股收益为（0.83 美元），超出分析师共识预期的（1.01 美元）0.18 美元。Syndax Pharmaceuticals 的净利润率为 -428.48%，股本回报率为 -130.47%。该公司在本季度的收入为 3,796 万美元，而分析师预期为 2,664 万美元。在去年同期，该公司每股收益为（0.80 美元）。与去年同期相比，该公司的收入增长了 984.5%。股票研究分析师预测 Syndax Pharmaceuticals, Inc. 本年度将发布 -3.72 美元的每股收益。</p>
<h2>内部买卖情况</h2>
<p>在相关消息中，首席执行官 Michael A. Metzger 于 7 月 16 日星期三出售了 7,534 股公司股票。股票以平均价格 9.29 美元出售，总交易额为 69,990.86 美元。出售完成后，首席执行官直接持有公司 298,661 股，价值 2,774,560.69 美元。这代表其持股减少了 2.46%。该交易已在向 SEC 提交的文件中披露，文件可通过此链接获取。4.10% 的股票由公司内部人士持有。</p>
<h2>机构投资者对 Syndax Pharmaceuticals 的看法</h2>
<p>一些对冲基金和其他机构投资者最近增加或减少了在 SNDX 的持股。Soleus Capital Management L.P. 在第四季度将其在 Syndax Pharmaceuticals 的持股增加了 128.4%。Soleus Capital Management L.P. 目前持有该公司 2,492,000 股股票，价值 32,944,000 美元，在此期间又购买了 1,401,016 股。Stempoint Capital LP 在第二季度将其在 Syndax Pharmaceuticals 的持股增加了 48.4%。Stempoint Capital LP 目前持有该公司 2,372,634 股股票，价值 22,220,000 美元，在此期间又购买了 774,040 股。富兰克林资源公司在第二季度将其在 Syndax Pharmaceuticals 的持股增加了 14.5%。富兰克林资源公司目前持有该公司 2,359,677 股股票，价值 22,098,000 美元，在此期间又购买了 298,272 股。Geode Capital Management LLC 在第二季度将其在 Syndax Pharmaceuticals 的持股增加了 1.3%。Geode Capital Management LLC 目前持有该公司 2,049,350 股股票，价值 19,195,000 美元，在此期间又购买了 26,365 股。最后，Qube Research &amp; Technologies Ltd 在第二季度将其在 Syndax Pharmaceuticals 的持股增加了 99.5%。Qube Research &amp; Technologies Ltd 目前持有该公司 1,665,916 股股票，价值 15,601,000 美元，在此期间又购买了 831,067 股。</p>
<h2>关于 Syndax Pharmaceuticals</h2>
<p>(获取免费报告)</p>
<p>Syndax Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司，开发用于癌症治疗的疗法。其主要产品候选药物包括 revumenib，一种强效、选择性的小分子抑制剂，针对 KMT2A 重排的急性白血病和实体肿瘤的 menin-MLL 结合相互作用；以及 SNDX-6352 或 axatilimab，一种单克隆抗体，阻断集落刺激因子 1（CSF-1）受体，用于治疗慢性移植物抗宿主病（cGVHD）和特发性肺纤维化（IPF）患者。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 Syndax Pharmaceuticals 更好</li>
<li>便士股票适合你的投资组合吗？</li>
<li>深度低估，Micron Technologies 股票未考虑 AI</li>
<li>3 只医疗保健分红股票值得购买</li>
<li>世纪铝业：工业复苏的优质股票</li>
<li>如何投资小型股</li>
<li>思科系统：唯一需要拥有的 AI 股票收入投资者</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Syndax Pharmaceuticals 吗？</h2>
<p>在考虑 Syndax Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Syndax Pharmaceuticals 并不在名单上。</p>
<p>虽然 Syndax Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Syndax制药

<p>Syndax 制药（NASDAQ:SNDX）在午盘交易中股价上涨 4.4%，达到 14.04 美元。分析师们发布了各种评级，花旗集团和 BTIG 研究大幅上调了目标价格。该公司报告的季度每股收益为（-0.83 美元），超出预期，营收同比增长 984.5%。内部交易活动包括首席执行官 Michael A. Metzger 出售股份，机构投资者也增加了对公司的持股。该股票的市值为 12.4 亿美元，市场共识评级为 “适度买入”</p>

<p>Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report)'s share price was up 4.4% during mid-day trading on Thursday . The stock traded as high as $14.01 and last traded at $14.04. Approximately 449,627 shares traded hands during trading, a decline of 80% from the average daily volume of 2,224,287 shares. The stock had previously closed at $13.45.</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - 获取免费报告) 的股价在周四的午盘交易中上涨了 4.4%。该股最高交易价格为 14.01 美元，最后交易价格为 14.04 美元。交易期间大约有 449,627 股成交，较日均成交量 2,224,287 股下降了 80%。该股此前收盘价为 13.45 美元。</p>
</div><p>Get <strong>Syndax Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities research analysts have issued reports on SNDX shares. Citigroup lifted their target price on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, August 5th. BTIG Research lifted their target price on shares of Syndax Pharmaceuticals from $43.00 to $56.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, August 5th. Scotiabank lifted their target price on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a &#34;sector perform&#34; rating in a research report on Tuesday, May 6th. UBS Group dropped their target price on shares of Syndax Pharmaceuticals from $37.00 to $35.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, July 15th. Finally, Guggenheim reiterated a &#34;buy&#34; rating and set a $32.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $36.91.</p>
<div class="lb-trans"><p>几位股票研究分析师对 SNDX 股票发布了报告。花旗集团将 Syndax Pharmaceuticals 的目标股价从 46.00 美元上调至 51.00 美元，并在 8 月 5 日的研究报告中给予该公司 &#34;买入&#34; 评级。BTIG Research 将 Syndax Pharmaceuticals 的目标股价从 43.00 美元上调至 56.00 美元，并在 8 月 5 日的研究报告中给予该公司 &#34;买入&#34; 评级。加拿大丰业银行将 Syndax Pharmaceuticals 的目标股价从 16.00 美元上调至 17.00 美元，并在 5 月 6 日的研究报告中给予该公司 &#34;行业表现&#34; 评级。瑞银集团将 Syndax Pharmaceuticals 的目标股价从 37.00 美元下调至 35.00 美元，并在 7 月 15 日的研究报告中给予该公司 &#34;买入&#34; 评级。最后，古根海姆在 5 月 6 日的研究报告中重申了 &#34;买入&#34; 评级，并将 Syndax Pharmaceuticals 的目标股价设定为 32.00 美元。一位分析师给予该股 &#34;卖出&#34; 评级，一位给予 &#34;持有&#34; 评级，十位给予 &#34;买入&#34; 评级，一位给予 &#34;强力买入&#34; 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 &#34;适度买入&#34;，共识目标价为 36.91 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on SNDX</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 SNDX 股票分析</strong></p>
</div><h2>Syndax Pharmaceuticals Trading Up 6.6%</h2>
<div class="lb-trans"><h2>Syndax Pharmaceuticals 股价上涨 6.6%</h2>
</div><p>The stock has a market capitalization of $1.24 billion, a P/E ratio of -3.69 and a beta of 0.74. The company has a current ratio of 4.71, a quick ratio of 4.55 and a debt-to-equity ratio of 2.06. The stock's fifty day moving average price is $10.20 and its two-hundred day moving average price is $11.88.</p>
<div class="lb-trans"><p>该股市值为 12.4 亿美元，市盈率为 -3.69，贝塔值为 0.74。该公司的流动比率为 4.71，速动比率为 4.55，债务与股本比率为 2.06。该股的 50 日移动平均价格为 10.20 美元，200 日移动平均价格为 11.88 美元。</p>
</div><p>Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($1.01) by $0.18. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The company had revenue of $37.96 million during the quarter, compared to analyst estimates of $26.64 million. During the same period in the prior year, the business posted ($0.80) EPS. The firm's revenue was up 984.5% compared to the same quarter last year. Equities research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals (NASDAQ:SNDX - 获取免费报告) 最近在 8 月 4 日发布了季度财报。该公司报告季度每股收益为（0.83 美元），超出分析师共识预期的（1.01 美元）0.18 美元。Syndax Pharmaceuticals 的净利润率为 -428.48%，股本回报率为 -130.47%。该公司在本季度的收入为 3,796 万美元，而分析师预期为 2,664 万美元。在去年同期，该公司每股收益为（0.80 美元）。与去年同期相比，该公司的收入增长了 984.5%。股票研究分析师预测 Syndax Pharmaceuticals, Inc. 本年度将发布 -3.72 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖情况</h2>
</div><p>In related news, CEO Michael A. Metzger sold 7,534 shares of the company's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $9.29, for a total transaction of $69,990.86. Following the completion of the sale, the chief executive officer directly owned 298,661 shares in the company, valued at $2,774,560.69. This represents a 2.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 4.10% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Michael A. Metzger 于 7 月 16 日星期三出售了 7,534 股公司股票。股票以平均价格 9.29 美元出售，总交易额为 69,990.86 美元。出售完成后，首席执行官直接持有公司 298,661 股，价值 2,774,560.69 美元。这代表其持股减少了 2.46%。该交易已在向 SEC 提交的文件中披露，文件可通过此链接获取。4.10% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Syndax Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Syndax Pharmaceuticals 的看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SNDX. Soleus Capital Management L.P. lifted its position in shares of Syndax Pharmaceuticals by 128.4% in the 4th quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company's stock worth $32,944,000 after purchasing an additional 1,401,016 shares during the period. Stempoint Capital LP lifted its position in shares of Syndax Pharmaceuticals by 48.4% in the 2nd quarter. Stempoint Capital LP now owns 2,372,634 shares of the company's stock worth $22,220,000 after purchasing an additional 774,040 shares during the period. Franklin Resources Inc. lifted its position in shares of Syndax Pharmaceuticals by 14.5% in the 2nd quarter. Franklin Resources Inc. now owns 2,359,677 shares of the company's stock worth $22,098,000 after purchasing an additional 298,272 shares during the period. Geode Capital Management LLC lifted its position in shares of Syndax Pharmaceuticals by 1.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,049,350 shares of the company's stock worth $19,195,000 after purchasing an additional 26,365 shares during the period. Finally, Qube Research &amp; Technologies Ltd lifted its position in shares of Syndax Pharmaceuticals by 99.5% in the 2nd quarter. Qube Research &amp; Technologies Ltd now owns 1,665,916 shares of the company's stock worth $15,601,000 after purchasing an additional 831,067 shares during the period.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近增加或减少了在 SNDX 的持股。Soleus Capital Management L.P. 在第四季度将其在 Syndax Pharmaceuticals 的持股增加了 128.4%。Soleus Capital Management L.P. 目前持有该公司 2,492,000 股股票，价值 32,944,000 美元，在此期间又购买了 1,401,016 股。Stempoint Capital LP 在第二季度将其在 Syndax Pharmaceuticals 的持股增加了 48.4%。Stempoint Capital LP 目前持有该公司 2,372,634 股股票，价值 22,220,000 美元，在此期间又购买了 774,040 股。富兰克林资源公司在第二季度将其在 Syndax Pharmaceuticals 的持股增加了 14.5%。富兰克林资源公司目前持有该公司 2,359,677 股股票，价值 22,098,000 美元，在此期间又购买了 298,272 股。Geode Capital Management LLC 在第二季度将其在 Syndax Pharmaceuticals 的持股增加了 1.3%。Geode Capital Management LLC 目前持有该公司 2,049,350 股股票，价值 19,195,000 美元，在此期间又购买了 26,365 股。最后，Qube Research &amp; Technologies Ltd 在第二季度将其在 Syndax Pharmaceuticals 的持股增加了 99.5%。Qube Research &amp; Technologies Ltd 目前持有该公司 1,665,916 股股票，价值 15,601,000 美元，在此期间又购买了 831,067 股。</p>
</div><h2>About Syndax Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Syndax Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司，开发用于癌症治疗的疗法。其主要产品候选药物包括 revumenib，一种强效、选择性的小分子抑制剂，针对 KMT2A 重排的急性白血病和实体肿瘤的 menin-MLL 结合相互作用；以及 SNDX-6352 或 axatilimab，一种单克隆抗体，阻断集落刺激因子 1（CSF-1）受体，用于治疗慢性移植物抗宿主病（cGVHD）和特发性肺纤维化（IPF）患者。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Syndax Pharmaceuticals</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Deeply Undervalued, Micron Technologies Stock Isn’t Pricing in AI</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>Century Aluminum: A Premier Stock for the Industrial Resurgence</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Cisco Systems: The Only AI Stock Income Investors Need to Own</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Syndax Pharmaceuticals 更好</li>
<li>便士股票适合你的投资组合吗？</li>
<li>深度低估，Micron Technologies 股票未考虑 AI</li>
<li>3 只医疗保健分红股票值得购买</li>
<li>世纪铝业：工业复苏的优质股票</li>
<li>如何投资小型股</li>
<li>思科系统：唯一需要拥有的 AI 股票收入投资者</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Syndax Pharmaceuticals 吗？</h2>
</div><p>Before you consider Syndax Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Syndax Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Syndax Pharmaceuticals 并不在名单上。</p>
</div><p>While Syndax Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Syndax Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Syndax 制药（NASDAQ:SNDX）股价上涨 4.4% - 现在是买入的好时机吗？